AQST - Aquestive Therapeutics

-

$undefined

N/A

(N/A)

Aquestive Therapeutics NasdaqGM:AQST Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Location: 30 Technology Drive, Warren, NJ, 07059, United States | Website: https://www.aquestive.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

239.7M

Cash

68.66M

Avg Qtr Burn

-12.19M

Short % of Float

10.52%

Insider Ownership

5.57%

Institutional Own.

48.86%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) Details
Parkinson’s disease (OFF Episodes / motor fluctuations)

Approved

Quarterly sales

Approved

Quarterly sales

Exservan™ (riluzole) Oral Film Details
Amyotrophic Lateral Sclerosis (ALS)

Approved

Quarterly sales

Approved

Quarterly sales

NDA

Acceptance for review

Phase 2a

Initiation

AQST-119 Details
Erectile dysfunction

Failed

Discontinued